WCN26-2146 PROTECT POST HOC ANALYSIS: EFFICACY OF SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IgA NEPHROPATHY ≤12 MO VS >12 MO FROM KIDNEY BIOPSY